FLUBLOK QUADRIVALENT VACCINE: PROVEN IN A RANDOMIZED CONTROLLED TRIAL TO PREVENT MORE CASES OF INFLUENZA IN ADULTS 50+ compared with a standard-dose quadrivalent inactivated influenza vaccine.1,2

EFFICACY IN ADULTS 50+:

PRIMARY ENDPOINT:  The primary endpoint of the study was PCRa-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.

30% BETTER PROTECTION FROM INFLUENZA
compared with a standard-dose quadrivalent inactivated influenza vaccine1,2

SECONDARY ENDPOINT:  The secondary endpoint of the study was culture-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.

43% BETTER PROTECTION FROM INFLUENZA
compared with a standard-dose quadrivalent inactivated influenza vaccine1,2

a PCR = Polymerase chain reaction.

SAFETY IN ADULTS 50+: In this randomized controlled trial, the most common local and systemic adverse reactions to Flublok Quadrivalent vaccine include pain at the injection site, headache and fatigue.

THE ONLY QUADRIVALENT INFLUENZA VACCINE TO PROVIDE ALL OF THESE FEATURES:

· 3X the HAb (45 mcg HA per strain) of a standard-dose quadrivalent inactivated influenza vaccine1

· Comparable safety profile to a standard-dose quadrivalent inactivated influenza vaccine2

· Recombinant technology replicates all 4 recommended HA strains exactly2

b HA = Hemagglutinin antigen.

CHOOSE FLUBLOK QUADRIVALENT VACCINE TO HELP PROTECT YOUR PATIENTS 50+

INDICATION FOR FLUBLOK QUADRIVALENT VACCINE

Flublok Quadrivalent vaccine is indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Flublok Quadrivalent vaccine is approved for use in persons 18 years of age and older.

SELECT SAFETY INFORMATION

Flublok Quadrivalent vaccine should not be administered to anyone who has had a severe allergic reaction (eg, anaphylaxis) after a previous dose of the vacine or to any component of the vaccine.

Please click to see full Important Safety Information. Please click to see full Prescribing Information for Flublok Quadrivalent vaccine.

IMPORTANT SAFETY INFORMATION FOR FLUBLOK QUADRIVALENT VACCINE

Flublok Quadrivalent vaccine should not be administered to anyone who has had a severe allergic reaction (eg, anaphylaxis) after a previous dose of the vaccine or to any component of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks after receipt of a prior influenza vaccine, the decision to give Flublok Quadrivalent vaccine should be based on careful consideration of the potential benefits and risks.

The most common local adverse reactions to Flublok Quadrivalent vaccine include tenderness and pain at the injection site. The most common systemic reactions include headache, fatigue, myalgia, and arthralgia. Other adverse reactions may occur. Vaccination with Flublok Quadrivalent vaccine may not protect all individuals.

Before administration, please see the full Prescribing Information for Flublok Quadrivalent vaccine.

Flublok Quadrivalent vaccine is manufactured by Protein Sciences Corporation, a Sanofi company, and distributed by Sanofi Pasteur Inc. Flublok Quadrivalent vaccine (CPT®c code 90682) is a covered benefit under Medicare Part B.

c CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

References: 1. Flublok Quadrivalent vaccine [Prescribing Information]. Meriden, CT: Protein Sciences Corporation. 2. Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017;376:2427-2436.

VaxServe, Inc., 54 Glenmaura National Blvd. Suite 301, Moosic, PA 18507 www.vaxserve.com

VAX7554 | © 2019 VaxServe, Inc. | 6/19